From the Globe and Mail:
For years, men who suffer from erectile dysfunction have been able to use Viagra or similar medications to provide some lift to their sex life. But there has never been a specific drug to help men who peak too soon.
Now, a major pharmaceutical company, Janssen-Ortho Inc., has filed an application with Health Canada to market in this country a new drug designed to treat premature ejaculation.
"This is a really common problem," said Gerald Brock, a professor at the University of Western Ontario who has been involved with company-sponsored trials of the drug.
The condition, which can cause great emotional distress for men and their partners, is believed to affect up to one-third of males, Dr. Brock said. Basically, they lack sexual control and reach orgasm in less than two minutes.
Scientists have long suspected that serotonin, a chemical messenger in the brain, plays a role in the disorder. In fact, patients are sometimes treated with a class of antidepressants known as SSRIs (selective serotonin reuptake inhibitors), which affect serotonin levels. ...more
Showing posts with label dapoxetine. Show all posts
Showing posts with label dapoxetine. Show all posts
Tuesday, February 17, 2009
Thursday, February 12, 2009
J&J Ejaculation Pill, World’s First, Wins Approvals
From Bloomberg:
Johnson & Johnson won approval in Sweden and Finland for the first prescription pill to treat premature ejaculation, three years after U.S. regulators rejected the drug, the company said.
The drugmaker expects to win clearance for dapoxetine, to be sold as Priligy, in five more European nations and has applied for approval in Canada, Australia, Mexico, Turkey and six other countries, said Greg Panico, a spokesman for New Brunswick, New Jersey-based J&J, today in a telephone interview. The pill, taken a few hours before intercourse, should be in European drugstores by April, he said.
“There’s a globally significant market” for premature ejaculation treatments, Panico said. He declined to estimate sales.
Dapoxetine may generate $575 million a year by 2011 for the company, said Michael Weinstein, a JPMorgan Chase & Co. analyst in New York, in an Oct. 29 note to clients. It’s one of several drugs J&J is developing to replace revenue it expects to lose to generic competition to top-selling medications such as the antipsychotic Risperdal, he said. ...more
Johnson & Johnson won approval in Sweden and Finland for the first prescription pill to treat premature ejaculation, three years after U.S. regulators rejected the drug, the company said.
The drugmaker expects to win clearance for dapoxetine, to be sold as Priligy, in five more European nations and has applied for approval in Canada, Australia, Mexico, Turkey and six other countries, said Greg Panico, a spokesman for New Brunswick, New Jersey-based J&J, today in a telephone interview. The pill, taken a few hours before intercourse, should be in European drugstores by April, he said.
“There’s a globally significant market” for premature ejaculation treatments, Panico said. He declined to estimate sales.
Dapoxetine may generate $575 million a year by 2011 for the company, said Michael Weinstein, a JPMorgan Chase & Co. analyst in New York, in an Oct. 29 note to clients. It’s one of several drugs J&J is developing to replace revenue it expects to lose to generic competition to top-selling medications such as the antipsychotic Risperdal, he said. ...more
Subscribe to:
Posts (Atom)